Ritmonorm (propafenone hydrochloride) coated tablets 150 mg. №50


Prevention and treatment: ventricular arrhythmias; paroxysmal supraventricular tachyarrhythmias, including the paroxysmal form of atrial flutter/fibrillation and paroxysmal reentri-tachycardia involving the AV node or additional pathways, if standard therapy is ineffective or contraindications for its implementation.



Composition and form of release
The main active ingredient is propafenone hydrochloride, it also contains excipients. Produced in tablet form.

Ritmonorm is a drug from the group of IC class antiarrhythmic drugs. It is prescribed for the treatment and prevention of ventricular arrhythmias, as well as paroxysmal supraventricular tachyarrhythmias, including paroxysmal atrial fibrillation / flutter, paroxysmal circular tachycardias with the inclusion of the atrioventricular node or auxiliary pathways. Propafenone has the property of exerting a stabilizing effect on the myocardial septum.

When treating with Ritmonorm, the patient has a decrease in spontaneous excitability, due to an increase in the sensitivity threshold of the myocardium. At the same time, the myocardium decreases electroexcitability due to an increase in the threshold of ventricular fibrillation.

Do not prescribe to patients who are allergic to porpafenone or other additional substances, as part of Rimonorm, or to those taking ritonavir.
Also, one should not resort to treatment with Ritmonorm for Brugada syndrome, organic heart disease, cardiogenic shock, bradycardia, sinus node disorder, atrioventricular block, atrial conduction disorder, distal blockade and blockade of the His bundle. Also, the drug is contraindicated in patients with impaired water and electrolyte balance, low blood pressure, and severe lung disease.
Use with caution for the treatment of patients with violations of the hepatobiliary system, liver, kidneys, heart failure, as well as patients with built-in pacemakers.

Application during pregnancy and lactation
There is no data that would indicate the complete safety of the use of Hexasprey for women during the period of bearing a child, because clinical trials of the drug on pregnant women are not carried out. Lactation during treatment with Ritmonorm should be canceled.

Method of administration and dosage
They start taking Ritmonorm exclusively in a hospital, orally, after eating, drinking water. The dosage is selected individually, after monitoring the heart rate, blood pressure, electrocardiogram.
The starting dose is 150 mg 3 times a day. After 3 days, it is permissible to double a single dose, but take the drug twice a day. It is allowed to increase it to three times a day, three times a day, up to the maximum allowable 900 mg per day.
If the patient weighs up to 70 kg, the dose should be reduced for patients suffering from disorders of the hepatobiliary system, kidneys, and elderly patients.
The effect of taking Ritmonorm increases when taken with anesthetics and drugs that can inhibit myocardial function.

An overdose of Ritmonorm can lead to death. Undesirable changes in the work of the myocardium may occur, pressure may drop. Overdose symptoms may also be drowsiness, convulsions. Dialysis is ineffective. Treatment for overdose should focus on maintaining heart muscle function. Symptomatic treatment is also prescribed.

Side effects
Reception of Ritmonorm causes various side effects. Probably the development of agranulocytosis, thrombocytopenia, purpura, anemia, leukopenia, hematomas, granulocytopenia, may increase the bleeding time. Disturbances from the central nervous system (disturbances of sleep, speech, vision) are widespread; cardiovascular system (various disorders of the heart, from tachycardia to heart failure); from the gastrointestinal tract (epigastric pain, gastroenteritis); liver function (jaundice, cholestasis, hepatitis); kidney (nephrosis, failure).
It is also possible to develop erectile dysfunction, arthralgia, allergic skin reactions.

Storage conditions and periods
Stored for up to 3 years at temperatures up to + 25 ° C.